Report Sections

See All Reports

  • HP:0002960: Autoimmunity
  • Pneumonia (361) Abnormality of the cardiovascular system (36) Respiratory tract infection (36) Neoplasm (29) Hypoxemia (28) Diabetes mellitus (25) Depressivity (24) Thromboembolism (23) Acute kidney injury (22) Abnormal lung morphology (21) Anosmia (19) Hypertension (18) Abnormality of coagulation (15) Pulmonary embolism (15) Pulmonary fibrosis (15) Stroke (14) Arthritis (14) Interstitial pneumonitis (14) Myocardial infarction (12) Type II diabetes mellitus (12) Deep venous thrombosis (11) Rheumatoid arthritis (10) Leukemia (10) Respiratory distress (10) Low levels of vitamin D (10) Behavioral abnormality (9) Mental deterioration (9) Chronic pain (9) Congestive heart failure (8) Myocarditis (8) Type I diabetes mellitus (8) Sepsis (8) Infertility (7) Abnormality of the liver (7) Lymphopenia (7) Inflammation of the large intestine (7) Pulmonary obstruction (7) Pulmonary insufficiency (7) Immunodeficiency (6) Systemic lupus erythematosus (6) Chronic pulmonary obstruction (6) Abnormality of the gastrointestinal tract (6) Neoplasm of the lung (6) Encephalopathy (5) Obesity (5) Lymphoma (5) Autoimmunity (5) Breast carcinoma (5) Disseminated intravascular coagulation (5) Fatigue (5) Abnormality of the kidney (4) Coronary artery atherosclerosis (4) Cardiac arrest (4) Headache (4) Colon cancer (4) Arrhythmia (4) Carcinoma (4) Hypercoagulability (4) Autistic behavior (3) Seizure (3) Cardiomyopathy (3) Dysphagia (3) Migraine (3) Pulmonary arterial hypertension (3) Asthma (3) Bronchiectasis (3) Neoplasm of the pancreas (3) Psoriasiform dermatitis (3) Attention deficit hyperactivity disorder (3) Cutaneous melanoma (3) Neoplasm of head and neck (3) Pulmonary edema (3) Insomnia (3) Neoplasm of the large intestine (3) Renal insufficiency (2) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Psychosis (2) Autism (2) Dementia (2) Abnormality of the endocrine system (2) Abnormality of the thyroid gland (2) Jaundice (2) Hepatic fibrosis (2) Premature birth (2) Abnormal heart morphology (2) Abnormality of blood and blood-forming tissues (2) Fever (2) Diarrhea (2) Hypothermia (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Encephalitis (2) Obstructive sleep apnea (2) Male infertility (2) Stillbirth (2) Paroxysmal atrial fibrillation (2) Lymphoid leukemia (2) Myeloproliferative disorder (2) Chronic lymphatic leukemia (2) Renal cell carcinoma (2) Multiple myeloma (2) Abnormal anterior horn cell morphology (2) Amyotrophic lateral sclerosis (2) Sleep apnea (2) Cystoid macular edema (2) Hemeralopia (2) Arteritis (2) Chronic kidney disease (2) Cervix cancer (2) Cholangitis (2) Cholangiocarcinoma (2) Myositis (2) Neuroendocrine neoplasm (2) Neoplasm of the rectum (2) Mania (2) Nephritis (1) Menorrhagia (1) Conductive hearing impairment (1) Cataract (1) Amblyopia (1) Periodontitis (1) Abnormality of the nervous system (1) Oligospermia (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Abnormality of the skin (1) Lymphedema (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Spastic diplegia (1) Hemiparesis (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic failure (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Cor pulmonale (1) Tachycardia (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Angina pectoris (1) Pancreatitis (1) Premature rupture of membranes (1) Weight loss (1) Thrombocytopenia (1) Autoimmune thrombocytopenia (1) Gastroesophageal reflux (1) Anorexia (1) Esophageal varix (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Hyperkinetic movements (1) Alzheimer disease (1) Increased intracranial pressure (1) Colitis (1) Biliary cirrhosis (1) Hypotension (1) Vascular dilatation (1) Atherosclerosis (1) Osteoarthritis (1) Tachypnea (1) Hypoventilation (1) Myelodysplasia (1) Neoplasm of the liver (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Reduced factor VIII activity (1) Skeletal muscle atrophy (1) Myalgia (1) Muscular dystrophy (1) Neonatal death (1) Increased body weight (1) Neoplasm of the nervous system (1) Malnutrition (1) Thrombophlebitis (1) Ventricular tachycardia (1) Acute myeloid leukemia (1) Dilatation of the cerebral artery (1) Knee osteoarthritis (1) Monoclonal immunoglobulin M proteinemia (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the stomach (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Renal neoplasm (1) Uterine neoplasm (1) Testicular neoplasm (1) Intestinal atresia (1) Tonsillitis (1) Inflammatory abnormality of the skin (1) Placental abruption (1) Postprandial hyperglycemia (1) Endometrial carcinoma (1) Erythroid hypoplasia (1) Asterixis (1) Glioblastoma multiforme (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Morphea (1) Allergy (1) Non-Hodgkin lymphoma (1) Retinal vein occlusion (1) Heart block (1) Dyspareunia (1) Ductal carcinoma in situ (1) Endometriosis (1) Cardiogenic shock (1) Vulvar neoplasm (1) Addictive behavior (1) Femur fracture (1) Neonatal sepsis (1) Glue ear (1) Neoplasm of the central nervous system (1) Abnormality of movement (1) Ulcerative colitis (1) Crohn's disease (1) Endocarditis (1) Toxemia of pregnancy (1) Neoplasm of the larynx (1) Ovarian neoplasm (1) Vaginal neoplasm (1) Cellulitis (1) Bulimia (1) Atelectasis (1) Esophageal neoplasm (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0002960: Autoimmunity

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (7)


    Name (Synonyms) Correlation
    drug555 CLIA of IgG and IgM against SARS-Cov-2 Wiki 0.45
    drug2689 Questionnaire by phone call Wiki 0.45
    drug3067 Skin biopsy Wiki 0.45
    Name (Synonyms) Correlation
    drug554 CLBS119 Wiki 0.45
    drug557 CNM-ZnAg Wiki 0.45
    drug481 Blood sampling Wiki 0.32
    drug2448 Placebo Wiki 0.02

    Correlated MeSH Terms (13)


    Name (Synonyms) Correlation
    D001327 Autoimmune Diseases NIH 1.00
    D012859 Sjogren's Syndrome NIH 0.52
    D012213 Rheumatic Fever NIH 0.52
    Name (Synonyms) Correlation
    D008180 Lupus Erythematosus, Systemic NIH 0.37
    D001167 Arteritis NIH 0.32
    D012216 Rheumatic Diseases NIH 0.27
    D025241 Spondylarthritis NIH 0.26
    D011111 Polymyalgia Rheumatica NIH 0.26
    D013700 Giant Cell Arteritis NIH 0.26
    D001168 Arthritis NIH 0.23
    D015535 Arthritis, Psoriatic NIH 0.22
    D003095 Collagen Diseases NIH 0.15
    D001172 Arthritis, Rheumatoid NIH 0.13

    Correlated HPO Terms (4)


    Name (Synonyms) Correlation
    HP:0002725 Systemic lupus erythematosus HPO 0.37
    HP:0012089 Arteritis HPO 0.32
    HP:0001369 Arthritis HPO 0.24
    Name (Synonyms) Correlation
    HP:0001370 Rheumatoid arthritis HPO 0.14

    Clinical Trials

    Navigate: Correlations   HPO

    There are 5 clinical trials


    1 Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease

    This epidemiological, transversal, cohort study aims to determine the potential influence of an active long-term hydroxychloroquine intake over the prevalence of a history of symptoms evocative of a COVID-19 infection in patients with a history of systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome or psoriatic arthritis, during the epidemic period in France. The information is gathered using a standardized questionnaire, by phone call.

    NCT04345159
    Conditions
    1. SARS-CoV-2
    2. Systemic Lupus Erythematosus
    3. Rheumatoid Arthritis
    4. Sjogren's Syndrome
    5. Psoriatic Arthritis
    Interventions
    1. Other: Questionnaire by phone call
    MeSH:Arthritis Arthritis, Psoriatic Sjogren's Syndrome Lupus Erythematosus, Systemic Autoimmune Diseases
    HPO:Arthritis Autoimmunity Polyarticular arthritis Systemic lupus erythematosus

    Primary Outcomes

    Description: Adjusted Odds Ratio measuring the association between an exposure to long-term hydroxychloroquine intake and a history of symptoms compatible with a COVID-19 infection.

    Measure: Adjusted Odds Ratio

    Time: 4 months after inclusion
    2 Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases : a Retrospective Multicenter Observational Study

    Since December 2019, an international outbreak of respiratory illnesses caused by SARS-CoV-2 called covid-19 has become a global challenge. In France, while the first cases were reported in January, more than 20 000 cases were confirmed at end of March. Early estimations from epidemiological data seem to show that 18-20% of patients with confirmed covid-19 are admitted in an intensive care unit (ICU). Patients with chronic inflammatory rheumatism, auto-immune or auto-inflammatory rare and non-rare diseases are susceptible to severe covid-19 (i.e ICU) due to the specific therapeutic management of their illness (corticosteroid, immunosuppressive and immunomodulatory drugs,..). No data are available for this particular population in France. This retrospective multicentre observational study aims to evaluate the frequency of severe forms of covid-19 and risk factors associated with specific outcomes in covid-19 in patients with chronic inflammatory rheumatism, auto-immune or auto-inflammatory rare and non-rare diseases.

    NCT04353609
    Conditions
    1. Sars-CoV2
    2. Chronic Inflammatory Rheumatism
    3. Autoimmune Diseases
    MeSH:Rheumatic Fever Rheumatic Diseases Collagen Diseases Autoimmune Diseases
    HPO:Autoimmunity

    Primary Outcomes

    Measure: Proportion of patients presenting a severe form of covid-19 requiring an intensive care unit admission or leading to death

    Time: From Baseline up to Day 21 after first symptoms of covid-19

    Secondary Outcomes

    Measure: Proportion of patients who die from a severe form of covid-19

    Time: From Baseline up to Day 21 after first symptoms of covid-19

    Measure: Proportion of patients who present an history of diabetes according to medical records

    Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

    Measure: Proportion of patients who present obesity (validated by Body Mass Index value > 30 kg/cm2)

    Time: At the set-up of first symptoms of covid-19 (Baseline visit)

    Measure: Proportion of patients who present an history of Chronic Pulmonary Obstructive Disease according to medical records

    Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

    Measure: Proportion of patients who present an history of Asthma according to medical records

    Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

    Measure: Proportion of patients who present an history of Hypertension according to medical records

    Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

    Measure: Proportion of patients who present an history of cardiac disease according to medical records

    Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

    Measure: Proportion of patients who present an history of Pulmonary Interstitial Disease according to medical records

    Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

    Measure: Proportion of patients who present an history of stroke according to medical records

    Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

    Measure: Proportion of patients who present an history of angiotensin-converting-enzyme inhibitor according to medical records

    Time: Before the set-up of first symptoms of covid-19 (Baseline visit)

    Measure: Proportion of patients who present an history of cancer according to medical records

    Time: Before the set-up of first symptoms of covid-19 (Baseline visit)
    3 Prevalence, Seroconversion and Impact of COVID-19 in Autoimmune Diseases in Europe

    The coronavirus disease 2019 (COVID-19) pandemic is a potentially fatal disease that represents a great global public health concern. In European countries such as Spain, Italy, Germany, Portugal, England and France, the pandemic has been of utmost importance. To date, no treatment has been robustly validated, and two theoretically opposite therapeutic strategies are proposed, based either on antiretroviral therapy or on immunomodulating agents. In this complex context, people living with immune-mediated inflammatory diseases (IMID) raise specific concerns due to their potentially increased risk of infections or of severe infections. Among IMID, Sjögren's syndrome, systemic lupus erythematosus, rheumatoid arthritis, spondyloarthritis and giant cell arteritis are some key diseases. In this cross-sectional, observational, multi-centric study, the investigators aim to assess both clinical and serological prevalence of COVID-19 among samples of IMID patients in Europe. In parallel, the investigators aim to compare the prevalence of COVID-19 seroconversion across these five IMIDs, their penetration across different 6 European countries (France, Italy, Spain, Germany, United Kingdom and Portugal), and to assess the severity of COVID-19 in these patients. Moreover, changes in treatment will be assessed, including immunomodulatory tapering or discontinuation, its causes over the outbreak period, as well as the incidence of IMID flares and their severity over this same period. Finally, patient's perceptions towards the pandemic will be evaluated and compared to medication beliefs. Data will be collected through questionnaires during medical visit or phone consultation and serological tests will be performed within routine blood collection. As so, all study procedures are comprised within usual care. Through this study the investigators expect to have a better knowledge of the clinical and serological prevalence of COVID-19 in IMID across Europe, along with the psychological, clinical, and therapeutic impact of COVID-19 in this particular patient population.

    NCT04397237
    Conditions
    1. COVID-19
    2. Systemic Lupus Erythematosus
    3. Sjogren's Syndrome
    4. Axial Spondyloarthritis
    5. Rheumatoid Arthritis
    6. Giant Cell Arteritis
    MeSH:Arthritis Arthritis, Rheumatoid Sjogren's Syndrome Spondylarthritis Polymyalgia Rheumatica Giant Cell Arteritis Arteritis Lupus Erythematosus, Systemic Autoimmune Diseases
    HPO:Arteritis Arthritis Autoimmunity Polyarticular arthritis Rheumatoid arthritis Systemic lupus erythematosus

    Primary Outcomes

    Description: ELISA tests for COVID-19 antibodies

    Measure: COVID-19 seroconversion

    Time: 1 day, during routine blood collection

    Description: Case report form filled by the health professional

    Measure: COVID-19 infection

    Time: During medical visit or phone consultation, up to 2 hours

    Secondary Outcomes

    Description: Descriptive analysis for each disease's rate

    Measure: Seroconversion rate by disease

    Time: 1 day, during routine blood collection

    Description: Descriptive analysis for each country's rate

    Measure: Penetration across Europe

    Time: 1 day, during routine blood collection

    Description: World Health Organization ordinal scale for clinical improvement at any given point of the infection, going from 0 to 8, where higher scores means worse outcome.

    Measure: COVID-19 severity

    Time: During medical visit, up to 1 hour

    Description: Descriptive analysis for overall and COVID-19-linked mortality rates

    Measure: COVID-19 mortality rate

    Time: During contact with family members, up to 1 hour

    Description: Case report form filled by the health professional

    Measure: COVID-19 impact on immunomodulatory treatment

    Time: During medical visit, up to 1 hour

    Description: Case report form filled by the patient

    Measure: Patient-reported flares

    Time: During medical visit, up to 1 hour

    Description: Fear of COVID-19 scale, going from 7 to 35, where higher scores means worse outcome.

    Measure: Patient's fears towards COVID-19

    Time: During medical visit, up to 1 hour

    Description: Beliefs about Medicines Questionnaire, going from 11 to 55, with higher scores indicating stronger beliefs regarding medicine.

    Measure: Patient's beliefs in their medicines towards COVID-19

    Time: During medical visit, up to 1 hour
    4 Mental Health Consequences of COVID19 Infection in the French Rheumatic Musculoskeletal Diseases (RMD) Cohort

    this observational, cross-sectional, national, comparative study, including RMD patients followed in hospital centres of the FAI²R Rare Diseases Healthcare Pathway network and specialist private practitioners caring for patients suffering from inflammatory rheumatism, systemic autoimmune diseases and auto-inflammatory diseases. The objective of the study is to compare RMD patients with COVID 19 infection (cases) to RMD patients who have not had COVID 19 infection (controls) on their mental health.

    NCT04510467
    Conditions
    1. Covid19
    2. Systemic Autoimmune Disease
    3. Inflammatory Rheumatism
    4. Auto Inflammatory Diseases
    MeSH:Rheumatic Fever Rheumatic Diseases Autoimmune Diseases
    HPO:Autoimmunity

    Primary Outcomes

    Measure: Frequency of PTSD depending on whether or not autoimmune patients have experienced COVID

    Time: at one month following exposure to the traumatic factor (i.e. one month from COVID-19 infection

    Secondary Outcomes

    Measure: Severity of PTSD depending on whether or not autoimmune patients have experienced COVID

    Time: at one month following exposure to the traumatic factor (i.e. one month from COVID-19 infection
    5 The Relationship Between COVID-19 and Autoimmune Diseases, Lessons From Practice

    The study explore the relationship between COVID-19 and the induction of autoimmune diseases.

    NCT04558203
    Conditions
    1. Covid19
    MeSH:Autoimmune Diseases
    HPO:Autoimmunity

    Primary Outcomes

    Description: incidence of autoimmune conditions

    Measure: incidence of autoimmune conditions

    Time: Two-weeks

    HPO Nodes


    Protein Mutations 3
    D89E S1009A V600E
    SNP 0

    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


    HPO Nodes


    Protein Mutations 3
    D89E S1009A V600E
    SNP 0

    Reports

    Data processed on December 13, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook